Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (JNJ) reported a 77% response rate for its investigational RYBREVANT FASPRO combination in first-line advanced head and neck cancer.
Phase 1b/2 OrigAMI-4 Cohort 5 tested subcutaneous amivantamab with pembrolizumab and up to six carboplatin cycles. Among 22 patients without HPV-associated oropharyngeal cancer, confirmed tumor responses occurred in 77%, including complete responses in 14%; 65% of responses remained ongoing at median follow-up of 10.6 months. One-year overall survival was 77%. The seven patients with HPV-associated oropharyngeal cancer had a 29% response rate.
Common adverse events included anemia (73%), hypoalbuminemia (63%), thrombocytopenia (63%) and stomatitis (57%). The first-line Phase 3 OrigAMI-5 study is ongoing. A separate application for later-line head and neck cancer is under FDA Priority Review.
Johnson & Johnson (NYSE:JNJ) reported a 75 percent tumor response rate with investigational JNJ-6143 in previously treated advanced prostate cancer.
In the Phase 1 study's 50-mg cohort, 12 of 16 patients with measurable disease had a confirmed complete or partial response. Among 38 patients receiving that once-daily dose, 77 percent achieved a confirmed reduction of at least 50 percent in prostate-specific antigen (PSA), a blood marker used to monitor prostate cancer; 48 percent had reductions of at least 90 percent. At analysis, 71 percent remained on treatment, with median follow-up of 5.6 months.
Most treatment-related adverse events were mild to moderate. Adverse events led to four dose interruptions, one dose reduction and one treatment discontinuation. The company plans further development of the 50-mg once-daily dose, including a Phase 2 study in metastatic prostate cancer.
Johnson & Johnson (NYSE: JNJ) announced that perioperative ERLEADA plus hormone therapy reduced recurrence or death risk by 62% versus surgery alone.
The randomized Phase 3 PROTEUS substudy enrolled 408 patients with high-risk localized or locally advanced prostate cancer. Apalutamide plus androgen deprivation therapy, which suppresses androgen hormones, was given before and after surgery. At median follow-up of 37.8 months, median event-free survival was not reached with the regimen versus 19.1 months with surgery alone; three-year rates were 63% versus 41.4%. Metastasis or death risk was numerically 51% lower, while subsequent-treatment risk was 71% lower. Grade 3 or 4 treatment-emergent adverse events occurred in 31% versus 22%; neither arm reported treatment-emergent deaths. Overall survival follow-up continues. The regimen is not approved for this setting.
Johnson & Johnson (JNJ) reported new atrial fibrillation treatment results for its VARIPULSE Pro and investigational OMNYPULSE platforms at APHRS 2026.
VARIPURE evaluated 225 patients across 19 European centers, reporting 100% acute procedural success, a 0.4% primary adverse event rate and mean ablation duration of 17.9 minutes. The adverse event resolved without lasting effects. VARIPULSE Pro is available in several international markets but is not approved in the United States.
In Omny-IRE, involving 136 patients across 13 European centers, 82.5% remained free from documented atrial arrhythmia recurrence at 12 months under stringent monitoring, versus 90.1% under standard-of-care monitoring. The adverse event rate was 2.9%; all events resolved. Quality-of-life scores improved by a mean 25.5 points. Separately, a database analysis associated CARTO 3 use with lower AF-related acute-care utilization than EnSite.
Johnson & Johnson (JNJ) has launched its Shockwave C2 Aero Fly Coronary IVL Catheter in the U.S. to treat calcified coronary artery lesions.
The device uses intravascular lithotripsy (IVL), a pulse-based treatment. Johnson & Johnson says it cuts treatment time to 115 seconds from 230 seconds with Shockwave C2+ and C2 Aero, including pulsing and pauses. Pulses are delivered at 2 Hz, and pauses between cycles are reduced to five seconds, although pause time may vary by patient need. Shorter balloon inflation exposes patients to less temporary restriction of blood flow than prior Shockwave devices.
Johnson & Johnson (NYSE: JNJ) announced Phase 3 FUZION results showing TREMFYA maintained or improved fistula remission through 48 weeks. The randomized, placebo-controlled study enrolled adults with Crohn's disease and perianal fistulas, abnormal connections near the anus. Combined remission requires closure without drainage or new fistulas and no underlying fluid collections on MRI.
With 100 mg every 8 weeks, combined remission rose from 28% at Week 24 to 35% at Week 48. Results with 200 mg every 4 weeks remained consistent through Week 48. At Week 24, combined remission was 28% and 27% in the respective TREMFYA groups, versus 10% with placebo. More than 90% of all randomized patients completed treatment through Week 48. Safety findings were consistent with TREMFYA's established safety profile in Crohn's disease.
Johnson & Johnson (NYSE: JNJ) declared a fourth-quarter 2026 cash dividend of $1.34 per share on its common stock.
The dividend is payable on December 8, 2026, to shareholders of record at the close of business on November 24, 2026. The ex-dividend date is also November 24, 2026.
Johnson & Johnson (NYSE: JNJ) reported third-quarter 2026 sales of $25.4 billion and raised its full-year sales and adjusted earnings guidance. Sales rose 5.9% year over year. Net earnings fell 95.9% to $210 million, while diluted earnings per share fell 95.8% to $0.09. Adjusted EPS, which excludes intangible amortization and special items, declined 7.5% to $2.59.
Innovative Medicine sales rose 7.7% to $16,757 million; MedTech sales increased 2.5% to $8,642 million. The company now expects 2026 reported sales of $101.0–$101.4 billion and adjusted EPS of $11.05–$11.15. It completed the Firefly Bio acquisition and announced a collaboration with Sail Biomedicines. Regulatory milestones included U.S. market authorization for the OTTAVA surgical system, FDA approval of IMAAVY for warm autoimmune hemolytic anemia, and priority review of RYBREVANT FASPRO for advanced head and neck cancer.
Johnson & Johnson (JNJ) announced three-year Phase 3 results for TREMFYA in adults with moderately to severely active Crohn's disease.
At Week 144 in the GALAXI 2 and 3 long-term extensions, clinical remission reached 94% with 100 mg every eight weeks and 91% with 200 mg every four weeks, following intravenous induction. Endoscopic remission, measured by intestinal examination, reached 52% and 61%, respectively. Both regimens achieved 88% 90-day corticosteroid-free clinical remission. Overall, 74% of TREMFYA-treated patients remained on treatment through three years. Safety findings were consistent with the established Crohn's disease safety profile.
The remission rates reflect as-observed data: participants entered the extension, received at least one partial or complete dose, remained on treatment and had Week 144 data. Participants with dose adjustments were excluded.
Johnson & Johnson (JNJ) announced Phase 3 TREMFYA results showing greater fistula remission than placebo across Crohn's disease patient subgroups.
The prespecified FUZION analyses assessed Week 24 combined fistula remission. Previously reported overall rates were 28% with 100 mg injected under the skin every eight weeks and 27% with 200 mg every four weeks, versus 10% with placebo. Among patients with prior biologic exposure, corresponding rates were 21% and 29%, versus 5%. Higher remission rates than placebo were also reported in patients with greater intestinal disease activity and those with or without proctitis, or rectal inflammation.
Remission required closure of all external fistula openings without drainage or new fistulas, and no underlying fluid collections on MRI. Adverse events were consistent with TREMFYA's known Crohn's disease safety profile.